Vice President - Go-to-Market and Omnichannel Strategy
About the job
- 15+ years of progressive leadership experience in pharmaceutical, biotechnology, or life sciences.
- Deep expertise in commercial strategy, go-to-market planning, customer engagement, omnichannel marketing, or customer experience strategy.
- Demonstrated success developing enterprise omnichannel and go-to-market strategies in launch or high-growth environments.
- Strong understanding of customer journey design, segmentation, personalization, content strategy, channel planning, and analytics-driven marketing.
- Demonstrated success in high-growth, fast-paced biotechnology or specialty pharmaceutical environments, balancing strategy with execution amid evolving priorities.
- Proven ability to lead effectively through ambiguity, creating clarity, structure, and alignment while processes, capabilities, resources, and commercial models are still being established.
- Experience in pre-commercial, launch-stage, or rapidly scaling organizations, with a track record of building capabilities and sustainable operating models.
- Proven ability to influence cross-functional stakeholders and align complex organizations around a shared strategic vision.
- Experience partnering with commercial operations and I&A teams to drive execution of engagement strategies.
- Demonstrated success translating vision into executable plans while building new capabilities, processes, and cross-functional alignment in environments characterized by rapid growth and ambiguity.
- Ability to adjust strategies in response to changing market conditions, competitive dynamics, organizational priorities, and business needs.
- Proven ability to make informed decisions with incomplete information, exercise sound judgment, manage risk, and maintain momentum in a rapidly evolving business environment.
- Strong strategic agility, with the ability to shift between enterprise strategy, launch planning, and operational problem-solving as business needs require.
- Ability to simplify complex business challenges, influence senior leaders, and effectively engage stakeholders across all levels of the organization.
- Demonstrated ability to prioritize competing demands and allocate resources effectively while maintaining an enterprise perspective and delivering against critical business objectives.
- Entrepreneurial approach to action, continuous improvement, innovation, and problem-solving in situations with limited precedent or established best practices.
- Ability to foster accountability, collaboration, agility, and customer-centricity while developing high-performing teams and future leaders.
- Availability for in-person attendance at the NAP office in the Philadelphia area based on business needs and work requirements.
- Ability to travel based on business needs, including attendance at internal meetings and key company or industry events.
- Establish a clear and differentiated go-to-market strategy aligned with commercial launch objectives and long-term growth ambitions.
- Create an enterprise omnichannel strategy that delivers consistent, customer-centric engagement across stakeholder touchpoints.
- Define customer engagement frameworks, journey strategies, segmentation approaches, and personalization priorities that guide cross-functional execution.
- Build strategic governance, planning processes, and measurement frameworks that align marketing investments with business objectives.
- Enable data-driven decision-making through actionable customer insights, performance analytics, and optimization strategies.
- Partner with Commercial Operations and execution teams to ensure seamless activation of omnichannel engagement plans.
- Foster innovation through emerging technologies, AI-enabled engagement, and new customer engagement models.
- Establish a scalable strategic framework capable of supporting future products, indications, and global expansion.
- Develop and own the enterprise go-to-market and omnichannel marketing strategy for launch and future portfolio growth, translating brand objectives, customer insights, market dynamics, and business priorities into differentiated customer engagement strategies.
- Define the customer engagement framework, including customer journeys, segmentation, personalization, content strategy, channel strategy, and engagement principles, to guide marketing activation across healthcare providers, patients, and other key stakeholders.
- Provide strategic direction for launch readiness and customer engagement, ensuring go-to-market and omnichannel strategies support launch objectives, customer needs, and evolving market opportunities.
- Advance measurement, innovation, and capability development through customer insights, analytics, AI-enabled solutions, and emerging engagement approaches, establishing scalable frameworks for future launches and long-term growth.
- Establish and lead the go-to-market and omnichannel strategy function, initially operating as a hands-on strategic leader.
- Build organizational capabilities, talent, and operating foundations required to support future growth and commercialization.
About the company
NewAmsterdam Pharma develops oral therapies for cardiometabolic diseases and runs late-stage clinical programs around obicetrapib, a CETP inhibitor aimed at lowering LDL-cholesterol in high-risk cardiovascular disease patients. Its pipeline includes a fixed-dose combo of obicetrapib and ezetimibe in Phase 2 (ROSE2) and three Phase 3 trials (BROADWAY, BROOKLYN, and PREVAIL) to evaluate obicetrapib in HeFH, ASCVD, and as a cardiovascular outcomes trial. Founded in 2019 and based in Naarden, the Netherlands, the company focuses on transforming lipid management and cardiovascular risk reduction through targeted CETP inhibition.
Company Size
51-200
Company Stage
IPO
Headquarters
Naarden, Netherlands
Founded
2019
Get referred to NewAmsterdam Pharma
See people who can refer or advise you
Simplify's Take
What believers are saying
- EMA, UK, and Swiss decisions expected in 2H2026 can unlock Germany and UK launches.
- June 2026 cash of $678.3 million funds PREVAIL, RUBENS, and commercialization through 2027.
- BROADWAY and BROOKLYN showed LDL-C lowering with placebo-like tolerability, supporting physician adoption.
What critics are saying
- PREVAIL interim data in 1Q2027 decides the entire platform; failure crushes NewAmsterdam.
- Merck's July 2026 oral PCSK9 approval steals cardiology mindshare before Menarini launches.
- COO Douglas Kling resigned effective August 14, 2026, signaling execution strain before launches.
What makes NewAmsterdam Pharma unique
- Obicetrapib is the only late-stage oral CETP inhibitor; Europe approved it in July 2026.
- NewAmsterdam pairs monotherapy and ezetimibe FDC across HeFH, ASCVD, and PREVAIL programs.
- Menarini commercialization in Europe gives NewAmsterdam royalties and milestones without building a salesforce.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Remote Work Options
Growth & Insights and Company News
6 month growth
0%1 year growth
-1%2 year growth
0%The European Commission has granted marketing authorisation for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination), marking the first global regulatory approval of obicetrapib. The approval, announced by NewAmsterdam Pharma and Menarini Group, covers treatment for patients with primary hypercholesterolaemia and mixed dyslipidaemia. The authorisation is supported by Phase 3 clinical trials demonstrating LDL cholesterol reductions of up to 40% with obicetrapib monotherapy and approximately 50% when combined with ezetimibe. The treatments showed a tolerability profile comparable to placebo. Menarini holds exclusive commercialisation rights in Europe. NewAmsterdam is entitled to tiered double-digit percentage royalties on net sales and up to €833 million in potential milestone payments. The companies continue advancing obicetrapib's clinical development through multiple ongoing Phase 3 trials, including the PREVAIL cardiovascular outcomes study.
NewAmsterdam Pharma to participate at upcoming investor conferences in September. NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) - NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences: * Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Wednesday, September 9, 2026. Michael Davidson, M.D., Chief Executive Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 3:45 p.m. ET on Wednesday, September 9. * Cantor Global Healthcare Conference 2026 in New York, NY on Thursday, September 10, 2026. Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 2:45 p.m. ET on Thursday, September 10. Live webcasts of both presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcasts, archived replays will be available on the Company's website. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Media Contact Real Chemistry on behalf of NewAmsterdam Christian Edgington P: 1-513-310-6410 [email protected] Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected]
NewAmsterdam Pharma announces upcoming presentations at the European Society of Cardiology (ESC) Congress 2026. NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) - NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data from its obicetrapib development program at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 - 31, 2026 in Munich, Germany. Presentation details are as follows: Title: Determinants of Short Term Lp(a) Variability in Phase 3 Obicetrapib Trials Session Title: Novel Lipid Lowering Therapies for Residual Risk Session Number: 3579 Moderated Poster Presentation Date and Time: Friday, August 28, 2026 at 10:15-11:00 CET Location: Station 2, Research Gallery Hall A1 Presenters: John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer, NewAmsterdam Pharma Title: Pooled On-Treatment Lipid-Lowering Efficacy of the CETP Inhibitor Obicetrapib in Phase III Trials Session Title: Lipid Lowering and Cardiovascular Outcomes Session Number: 3582 Moderated Poster Presentation Date and Time: Sunday, August 30, 2026 at 10:15-11:00 CET Location: Station 2, Research Gallery Hall A1 Presenter: Mathijs A.C. de Kleer Title: Extreme HDL-C Associated Increased Mortality is Explained by Confounding Due to Progressively Increasing Alcohol-Induced Multisystem Morbidity Session Title: Lipids and Myocardial Infarction Session Number: 3102 Oral Presentation Date and Time: Monday, August 31, 2026 at 12:30-12:40 CET Location: Science Box 5, Research Gateway Hall A1 Presenter: Brian A. Ference, M.D., MPhil, FACC, FESC About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. NewAmsterdam Pharma Company seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Media Contact Real Chemistry on behalf of NewAmsterdam Christian Edgington P: 1-513-310-6410 [email protected] Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected]
NewAmsterdam Pharma reported second quarter 2026 financial results and announced positive regulatory progress for obicetrapib, its cholesterol-lowering drug candidate. The European Medicines Agency's CHMP has recommended marketing authorisation for obicetrapib as both a monotherapy and in combination with ezetimibe for treating hypercholesterolemia and mixed dyslipidemia. A final European Commission decision is expected later this year. The company holds $678.3 million in cash, cash equivalents and marketable securities as of 30 June 2026, down from $728.9 million at year-end 2025. Second quarter net loss was $64.1 million compared to $17.4 million in the same period last year. NewAmsterdam plans an interim analysis of its PREVAIL cardiovascular outcomes trial in fourth quarter 2026, with results expected in first quarter 2027. Topline data from the RUBENS Phase 3 trial is anticipated by year-end 2026.
NewAmsterdam Pharma to host Investor Day on August 5, 2026. NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) - NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an Investor Day event for analysts and investors on August 5, 2026 beginning at 9:00 a.m. ET in New York City. Please join members of its management team, including: Michael Davidson, M.D., Chief Executive Officer; John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer; BJ Jones, Chief Commercial Officer; Ian Somaiya, Chief Financial Officer; and Matthew Philippe, Executive Vice President and Head of Investor Relations. A live webcast of the Investor Day event will be available, and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at ir.newamsterdampharma.com at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance. About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. NewAmsterdam Pharma Company seek to fill a significant unmet need for a safe, well-tolerated and convenient therapy that lowers LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Media Contact Real Chemistry on behalf of NewAmsterdam Christian Edgington P: 1-513-310-6410 [email protected] Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected]